Biopharma | April 14, 2026
Gennova CEO Dr Sanjay Singh sees strong innovation momentum for India’s biopharma sector
Veteran biopharma leader stressed that generic medicines must be viewed separately from biologics
Veteran biopharma leader stressed that generic medicines must be viewed separately from biologics
A major push to sharpen the future of cancer treatment is underway
The study’s multi-technology design is intended to improve reproducibility, strengthen regulatory-grade evidence generation
Outlines 1,500-member internal cadre, digital regulatory system, and faster SEC-led reviews
This event will bring together global stakeholders to explore India’s growing capabilities in pharma and biopharma innovation, research, and manufacturing
The two-day conference and exhibition features discussions on policy frameworks, AI-led drug discovery, next-generation technologies, and global competitiveness
The solution integrates key molecular cloning methods—including Golden Gate, Gibson assembly, and restriction/ligation—alongside primer design, Sanger sequencing analysis, and protein translation in a single application
Former Global Head of IT & Digital Transformation at Biocon Biologics steps into enterprise-wide technology leadership role
For the biopharma industry, the study strengthens the case for balancing immune-cell engagement with tolerability in antibody discovery platforms
The deal gives Vertex access to Halozyme’s Hypercon technology for up to three drug targets
Subscribe To Our Newsletter & Stay Updated
